Shares of Claris Lifesciences today surged over 5 per cent after the company said it underwent an audit by the USFDA for Pharmacovigilance in the last week of May and has not received any observations.
The stock gained 5.40 per cent to end at Rs 344.70 on BSE. During the day, it soared 11.90 per cent to Rs 366.
The company's market valuation rose by Rs 96.95 crore to Rs 1,880.95 crore.
On the volume front, 3.10 lakh shares of the company were traded on BSE during the day.
"Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s)," the company said in a BSE filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
